Product news

Share this article:

Pfizer granted a royalty-free license to the International Partnership for Microbicides (IPM) to try to develop Selzentry (maraviroc) in a cream or gel for the prevention of HIV infection. The agreement enables IPM to develop, manufacture and distribute a maraviroc-based microbicide in developing countries. Microbicides are products that could be applied vaginally or anally to prevent transmission of the human immunodeficiency virus that causes AIDS. Pfizer's CCR5 blocker was approved last August. The microbicides group also has agreements with Ortho Biotech unit Tibotec Pharmaceuticals, Merck, Bristol-Myers Squibb and Gilead Sciences to develop some of their HIV drugs. Pfizer granted a royalty-free license to the International Partnership for Microbicides (IPM) to try to develop Selzentry (maraviroc) in a cream or gel for the prevention of HIV infection. The agreement enables IPM to develop, manufacture and distribute a maraviroc-based microbicide in developing countries. Microbicides are products that could be applied vaginally or anally to prevent transmission of the human immunodeficiency virus that causes AIDS. Pfizer's CCR5 blocker, approved last August, was the second FDA-sanctioned drug licensed by IPM. The first was the Bristol-Myers Squibb/Gilead Sciences antiviral Viread (tenofovir). The microbicides group also has agreements with Ortho Biotech unit Tibotec Pharmaceuticals and with Merck to develop some of their HIV drugs.

 Intelence (etravirine), from J&J subsidiary Tibotec Pharmaceuticals, was approved for treating HIV infection in adults who have failed treatment with other antiretrovirals. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that helps to block an enzyme which HIV needs to multiply. The drug, approved for use in combination with other anti-HIV medications, received a priority review by the FDA.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.